Tobacco Harms, Nicotine Pharmacology, and Pharmacologic Tobacco Cessation Interventions for Women

Baraona, L. Kim; Lovelace, Dawn; Daniels, Julie L.; McDaniel, Linda R.

doi:10.1111/jmwh.12616

Cited by 26 publications

(23 citation statements)

References 71 publications

(197 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The emergence of tobacco dependence is primarily due to the psychoactive properties of nicotine. Nicotine has broad pharmacological effects on humans and animals [24]. Under first exposure to nicotine, either by inhalation or through other routes of administration, subjects report relaxation, alertness, dizziness, and nausea, amongst other effects [25].…”

Section: Introductionmentioning

confidence: 99%

C57BL/6 Substrain Differences in Pharmacological Effects after Acute and Repeated Nicotine Administration

et al. 2019

View full text Add to dashboard Cite

Tobacco smoking is the major cause of disability and death in the United States and around the world. In addition, tobacco dependence and addiction express themselves as complex behaviors involving an interplay of genetics, environment, and psychological state. Mouse genetic studies could potentially elucidate the novel genes and/or gene networks regulating various aspects of nicotine dependence. Using the closely related C57BL/6 (B6) mice substrains, recent reports have noted phenotypic differences within C57BL/6J (B6J) and C57BL/6N (B6N) mice for some drugs of abuse: alcohol, opiates, and cocaine. However, the differences in nicotine’s effects have not yet been described in these substrains. We examined the phenotypic differences in these substrains following the acute and repeated administration of nicotine in several pharmacological measures, including locomotion (after acute and repeated exposure), body temperature, nociception, and anxiety-like behaviors. We report substrain differences in the pharmacological effects of acute and repeated nicotine administration in the B6 substrains. Overall, we show enhanced nicotine sensitivity to locomotion, hypothermia, antinociception, and anxiety-like behaviors in the B6J mouse substrain compared to B6N. In the repeated administration paradigm, both the B6N and B6J substrains showed no sensitized locomotor responses after repeated exposure to nicotine at the two doses tested. This study thus provides evidence that the B6 mouse substrains may be useful for genetic studies to elucidate some of the genetic variants involved in tobacco dependence and addiction.

show abstract

Section: Introductionmentioning

confidence: 99%

C57BL/6 Substrain Differences in Pharmacological Effects after Acute and Repeated Nicotine Administration

et al. 2019

View full text Add to dashboard Cite

show abstract

“…We did not find any human studies that evaluated the effects of ENDS use during pregnancy on reproductive outcomes. One-third of the publications (n=34) consisted of reviews, with only 11 specifically addressing ENDS use during pregnancy or on the potential effects of ENDS use during pregnancy 8-19 . There were 21 reports of studies of fetal outcomes from pregnant animals or animal/tissue models, and 9 of these were designed to address ENDS prenatal exposure and its reproductive effects 20-26 .…”

Section: Resultsmentioning

confidence: 99%

The use of electronic nicotine delivery systems during pregnancy and the reproductive outcomes: A systematic review of the literature

Cárdenas¹,

Fischbach²,

Chowdhury³

2019

Tob. Induc. Dis.

View full text Add to dashboard Cite

INTRODUCTIONUse of electronic nicotine delivery systems (ENDS) among pregnant women is of great concern. To our knowledge the current literature provides conflicting views regarding the uncertainties of the effects of ENDS use during pregnancy on the health of the fetus.METHODSWe searched PubMed, CINAHL, and EMBASE, for the period 2007 to October 2017 for terms to identify publications on ENDS use during pregnancy and the reproductive outcomes. We updated the search for the period November 2017 to November 2018 using Ovid Medline. We obtained full text of articles and present a summary of the contents.RESULTSWe found no studies of pregnant women exposed to ENDS use and its effect on their fetus or neonates. However, there is a growing body of experimental studies in animals that suggest that nicotine in ENDS alters DNA methylation, induces birth defects, reduces the birth weight, and affects the development of the heart and lungs of their offspring. A large population-based cohort study in the United States estimated that 5% of pregnant women were current ENDS users in 2014; most of them also smoked cigarettes. Surveys conducted among practitioners indicate that there is a need to screen and counsel pregnant women. Systematic reviews and meta-analysis of studies of women who used smokeless tobacco during pregnancy suggest that prenatal nicotine alone is a risk factor for low birth weight, premature delivery, and stillbirth.CONCLUSIONSThere were no previous studies assessing the reproductive effects of ENDS use during pregnancy. However, prenatal exposure to nicotine is known to be harmful to the fetus and the pregnancy.

show abstract

“…Pharmaceutical support is underutilized due to lack of awareness and knowledge about the safety of smoking cessation medication during pregnancy. 66…”

Section: Pregnant Womenmentioning

confidence: 99%

Tobacco dependence treatment for special populations: challenges and opportunities

Castaldelli-Maia

Harutyunyan

Herbeć

et al. 2021

Braz. J. Psychiatry

View full text Add to dashboard Cite

Although smoking rates have declined in most of the countries in the world, there are population groups within these countries whose smoking rates remain significantly higher than the general population. These ''forgotten groups'' who have not been receiving the needed attention in tobacco control policies and tobacco cessation efforts include people with serious mental illness, substance use disorders, tuberculosis, people living with human immunodeficiency virus (HIV), lesbian-gaybisexual-transgender-queer people, and pregnant women. A number of steps are needed at the national level in countries where these disparities exist, including modifications to national smoking cessation treatment guidelines that address the special needs of these populations, as well as targeted smoking cessation research, since these populations are often not included in clinical trials. Because of the higher smoking prevalence in these populations, as well as their lower smoking cessation treatment success rates than the general population, more resources are needed if we are to reduce health disparities in these vulnerable populations. Additionally, we believe that more effort should be focused on integrating smoking cessation treatment in the specialized care settings frequented by these subpopulations.

show abstract

Tobacco Harms, Nicotine Pharmacology, and Pharmacologic Tobacco Cessation Interventions for Women

Cited by 26 publications

References 71 publications

C57BL/6 Substrain Differences in Pharmacological Effects after Acute and Repeated Nicotine Administration

C57BL/6 Substrain Differences in Pharmacological Effects after Acute and Repeated Nicotine Administration

The use of electronic nicotine delivery systems during pregnancy and the reproductive outcomes: A systematic review of the literature

Tobacco dependence treatment for special populations: challenges and opportunities

Contact Info

Product

Resources

About